China Pharma Holdings vs Traws Pharma
China Pharma Holdings is the larger business, with $4.1m of revenue in fiscal 2025 against $2.8m for Traws Pharma (1.5 times as much). Traws Pharma grew faster (1134.5% against -8.5%). Traws Pharma kept more of each dollar of sales as profit: a net margin of 328.7% against -76.9%.
| Latest fiscal year | China Pharma HoldingsCPHI, 2025 | Traws PharmaTRAW, 2025 |
|---|---|---|
| Revenue | $4.1m | $2.8m |
| Revenue growth | -8.5% | 1134.5% |
| Net income | −$3.2m | $9.2m |
| Operating margin | -78.2% | -640.7% |
| Net margin | -76.9% | 328.7% |
| Return on equity | -20.9% | — |
| Free cash flow | $88,937 | −$20.8m |
| Cash | $345,112 | $3.8m |
| Total debt | $3.3m | $0 |
| Debt to equity | 14.5% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 221 | — |
| Market value | $24.7m | $4.6m |
| Price vs our value range | — | — |
| Moat score | 26 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 0 sales |